To Study the Effect of Angiotensin Receptor Blockers on Diabetic Retinopathy

Abstract

BACKGROUNDDiabetic Retinopathy (DR) is the most common microvascular complication of Diabetes Mellitus (DM) and is the leading cause of blindness in working age adults of patients with type 1 and 2 DM. Large observational and randomised studies shown that optimal blood glucose and blood pressure control halt or regress the disease and limit the risk of progression to the proliferative stage and visual loss. Recently, evidence has also emerged that Renin-Angiotensin System (RAS) inhibitors may electively prevent or delay progression of retinopathy by acting on local RAS. Thus, metabolic and blood pressure control by RAS inhibition is to prevent or limit the onset of retinopathy and its progression towards visual-threatening stages.The aim of the study is to categorise and analyse grading of DR who are on currently ACE and ARBs unchanged for at least 2 years.